Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Diseases
100%
Recurrent Disease
80%
Methotrexate
60%
Cyclophosphamide
60%
Anthracycline
60%
Fluorouracil
60%
Chemotherapy
40%
Side Effect
20%
Estrogen Receptor
20%
Mortality Rate
20%
Adverse Event
20%
Cancer Mortality
20%
Cancer Recurrence
20%
Tamoxifen
20%
Primary Tumor
20%
Cancer Survival
20%
Treatment Group
20%
Nursing and Health Professions
Breast Cancer
100%
Combination Chemotherapy
100%
Diseases
55%
Recurrent Disease
44%
Randomization
44%
Methotrexate
33%
Fluorouracil
33%
Anthracycline
33%
Cyclophosphamide
33%
Mortality Rate
11%
Side Effect
11%
Rate Ratio
11%
Adverse Event
11%
Cancer Mortality
11%
Estrogen Receptor
11%
Primary Tumor
11%
Cancer Recurrence
11%
Cancer Survival
11%
Tamoxifen
11%
Treatment Group
11%
Medicine and Dentistry
Breast Cancer
100%
Combination Chemotherapy
100%
Diseases
55%
Recurrent Disease
44%
Fluorouracil
33%
Cyclophosphamide
33%
Methotrexate
33%
Anthracycline
33%
Adverse Event
11%
Side Effect
11%
Mortality Rate
11%
Primary Tumor
11%
Cancer Mortality
11%
Cancer Recurrence
11%
Contralateral
11%
Estrogen Receptor
11%
Tamoxifen
11%
Cancer Survival
11%
Chemotherapy
11%
Treatment Group
11%
Neuroscience
Cyclophosphamide
100%
Methotrexate
100%
Anthracycline
100%
Fluorouracil
100%
Adverse Effect
33%
Estrogen Receptor
33%
Chemotherapy Regimens
33%
Tamoxifen
33%
Mathematics
Randomized Trial
100%
Proportional Reduction
66%
Death Rate
33%